Infinity In-Licenses Portfolio Of PI3 Kinase Inhibitors For Inflammatory Diseases

Deal is the historically oncology-focused Infinity's first pipeline-building move since it began a strategic alliance with Purdue Pharma and the latter's European affiliate Mundipharma in late 2008.